162 related articles for article (PubMed ID: 33087019)
1. JAK2 mutation-positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: a case report.
Kondo H; Watanabe R; Okazaki S; Kuriyama K; Ochi T; Yamada G; Sugiura A; Chiba H; Tsukada A; Taniuchi S; Igarashi T; Kudo M; Harigae H; Fujii H
Mod Rheumatol Case Rep; 2020 Jul; 4(2):289-295. PubMed ID: 33087019
[TBL] [Abstract][Full Text] [Related]
2. Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis.
Sugimoto H; Matsuno S; Yamanaka N; Yumura W; Itabashi M; Takei T
CEN Case Rep; 2021 Feb; 10(1):46-52. PubMed ID: 32754805
[TBL] [Abstract][Full Text] [Related]
3. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
4. [From gene to disease; JAK2 and polycythaemia vera].
Koene HR; Biemond BJ; van der Schoot CE
Ned Tijdschr Geneeskd; 2007 Aug; 151(32):1784-7. PubMed ID: 17822250
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
6. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
7. Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.
Coskun ME; Height S; Dhawan A; Hadzic N
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710306
[TBL] [Abstract][Full Text] [Related]
8. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
9. Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review.
Hui S; Zhao J; Huo T; Dong L; Xie Y; Wang X; Zhang M
Medicine (Baltimore); 2024 Feb; 103(7):e36953. PubMed ID: 38363912
[TBL] [Abstract][Full Text] [Related]
10. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
11. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
13. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
14. Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations.
Ibrahim IK; Hassan R; Ali EW; Omer A
Asian Pac J Cancer Prev; 2019 Jan; 20(1):41-44. PubMed ID: 30677867
[TBL] [Abstract][Full Text] [Related]
15. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
16. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
Lussana F; Carobbio A; Randi ML; Elena C; Rumi E; Finazzi G; Bertozzi I; Pieri L; Ruggeri M; Palandri F; Polverelli N; Elli E; Tieghi A; Iurlo A; Ruella M; Cazzola M; Rambaldi A; Vannucchi AM; Barbui T
Br J Haematol; 2014 Nov; 167(4):541-6. PubMed ID: 25130523
[TBL] [Abstract][Full Text] [Related]
17. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
19. [Polycythemia vera and JAK-2 mutation in childhood: a case report].
Braconnier O; Monpoux F; Affanetti M; Bérard E; Sirvent N
Arch Pediatr; 2007 Oct; 14(10):1202-5. PubMed ID: 17693067
[TBL] [Abstract][Full Text] [Related]
20. Treating Immunoglobulin A Vasculitis in an Elderly Patient Using Steroids: A Clinical Study.
Ono K; Fukoe Y; Lee Y; Lee M; Watanabe M; Aoki T; Murakami M
In Vivo; 2019; 33(4):1325-1328. PubMed ID: 31280225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
